Global immunotherapy drugs market is estimated to be valued at USD 166.55 Bn in 2024 and is expected to exhibit a CAGR of 11.3% during the forecast period (2024-2031). Immunotherapy drugs utilize the body's immune system to fight cancer and other diseases. These drugs stimulate the immune system by either boosting existing immune cells or introducing new immune cells into the body. The major types of immunotherapies include monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and adoptive cell transfer therapies. Immunotherapy drugs are increasingly becoming the standard of care for various cancer types as these have been shown to provide long-lasting response rates with milder side effects compared to chemotherapy. The market has witnessed significant growth over the past few years driven by new drug approvals and increasing adoption across different disease indications.

Market Dynamics:

Global immunotherapy drugs market growth is driven by rising prevalence of cancer and other chronic diseases worldwide. The market has gained momentum due to factors such as an increase in R&D funding for developing novel immunotherapies, consistent FDA approvals of immunotherapies, and superiority over other available treatment options. However, high costs associated with these drugs along with reimbursement issues in some regions act as key restraints for this market. The market players are also investing in pipeline products for expanding the current treatment landscape to new indications.

Key Features of the Study:

• This report provides in-depth analysis of the global immunotherapy drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global immunotherapy drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., AstraZeneca, Amgen Inc., GSK plc., Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Fate Therapeutics., Gritstone bio, Incyte, Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., BioNTech SE, and Cellectis.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global immunotherapy drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immunotherapy drugs market.

Detailed Segmentation-

• Therapy Type:
  • Immune checkpoint inhibitors
  • Monoclonal antibodies
    • Naked monoclonal antibodies
    • Conjugated monoclonal antibodies
    • Bispecific monoclonal antibodies
  • Vaccines
    • Preventive Vaccines
    • Therapeutic Vaccines
  • Adoptive Cell Therapies
    • Tumor-infiltrating lymphocyte (TIL) therapy
    • CAR T-cell therapy
    • Engineered T-cell receptor (TCR) therapy
    • Natural killer (NK) cell therapy
  • Immune System Modulators
    • Interferons
    • Immunomodulators (IMiDs)
    • Interleukins
  • Oncolytic Virus Therapy
• Route of Administration:
  • Intravenous (IV)
  • Oral
  • Intramuscular
  • Subcutaneous 
  • Others
• Indication:
  • Cancer
    • Lung Cancer
    • Lymphoma
    • Breast Cancer
    • Skin Cancer
    • Bladder Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Others
  • Autoimmune Diseases
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Fate Therapeutics.
  • Gritstone bio
  • Incyte
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • BioNTech SE
  • Cellectis